Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
- Invokana Superior As Second Add-on to Metformin
- HbA1c Screening A Must In All Hospitals
- Electronics Said to Reduce Hypoglycemic Events
- Featuring Exclusive Interview with Dr. Joseph Aloi
- Long-Acting Weekly Semaglutide with Reduced Risks for CVD
- FDA Panal Approves Jardiance Claim to Cut Cardio Risks, Death
- Guest article by David Kliff, Diabetic Investor
- How to Improve What Really Matters: Quality of Life, Not Longevity
- by Featured Writer: Dr. Sheri Colberg, Ph.D., FACSM
Letter from the Editor
I just did a CE program for consultant pharmacists in Lake Mary, Florida. We were discussing the reasons why we may not try to work to perfection with our older patients. One of my colleagues brought up the 5-star ratings and how one of the measurements had to do with using statins in all diabetes patients. Over the past couple of years there have been studies — some published on our website — that could be interpreted as contradictory to that guideline. This led to a discussion on the quality of life versus longevity and how we play such a pivotal role with our patients. This week, Dr Sheri Colberg looks at what really matters in her feature “How to improve Quality of Life not Longevity.”
Another of our contributors, David Kliff, looks at how the use of the SGLT-2 Inhibitor, Empaglifozin, can improve A1Cs while reducing heart risks and possibly improving quality of life.
Announcements:
dLifeTV.com: Sunday, July 3, 7PM ET
From dLife.com: “Viewer Will Ryan shares what he has learned about having diabetes; dLife takes a trip on the diabetes bus; Jim Turner quizzes our diabetes knowledge on a fact or fiction diabetes testing procedure.” Sundays live online at dLifeTV.com at 7 PM ET, 6 PM CT, and 4 PM PT. Keep up on the latest dLife news at dLifeTV.com.
*****************************
We can make a difference!
*****************************
Dave Joffe, Editor-in-chief
This Week's Survey
We were at the ADA and AACE and have over 45 video interviews with some great information. Would you prefer to watch a video interview in its entirety, or an interview broken up into Q&A segments? Follow the link and let us know your opinion!
Newsflash: Expensive Drugs to Treat Diabetic Macular Edema Not Cost-Effective
The anti-vascular endothelial growth factor drugs ranibizumab and aflibercept are not cost-effective at their present prices, according to a study published online by JAMA Ophthalmology. DIC Advisory Board member Dr. A. Paul Chous, MA, OD, FAAO, shares his thoughts on the study results in this exclusive commentary.
Patient App
Challenge your Health IQ in this fun and educational health trivia app.
Do you know the minimum SPF needed to protect yourself from the sun’s harmful rays? Or how many seconds you should wash your hands to kill germs? Test your Health IQ to see how your health skills stack up.
Newsflash: FDA Approves Jardiance Claim to Cut Cardio Risks, Death
Test Your Knowledge
More stringent hyperglycemia management (target A1C 6-6.5%) in type 2 diabetes might be supported by which one of the following factors:
A. Long-standing disease duration
B. Moderate-severe vascular complications
C. Shorter life expectancy
D. Absent-few comorbidities
Are you right? Follow the link to find out!
Did you know: FDA panel to weigh change in use of Dexcom's glucose monitor
A public FDA advisory committee meeting is scheduled for next month to discuss whether Dexcom’s G5 Mobile Continuous Glucose Monitoring System device can be marketed as a replacement for fingerstick blood glucose meters. On July 21, 2016, the committee will discuss, make recommendations, and vote on information regarding a premarket approval application (PMA) panel-track supplement for a proposed change in intended use of Dexcom, Inc.’s, Dexcom G5® Mobile Continuous Glucose Monitoring System (CGM) device so that, in addition to tracking and trending interstitial fluid glucose concentrations, patients can use the device as a replacement for their blood glucose meters and make treatment decisions based on the interstitial fluid glucose concentration reported by the CGM.
New study indicates canagliflozin superior to glimepiride in lowering A1C.
Diabetes screening should be protocol test in all health centers, health fairs to prevent undiagnosed diabetes and avoid later complications.
New data presented at AACE shows hypoglycemic events are less likely in patients with diabetes treated with an electronic glycemic management system.
Novo Nordisk announced positive results on its pipeline GLP-1 candidate, semaglutide, from the phase IIIa trial, SUSTAIN 4 and 5.
Guest article by David Kliff, Diabetic Investor:
Panel further assessing date that SGLT-2 drug shows actual benefit for heart.
Featured Writer: Dr. Sheri Colberg, Ph.D., FACSM
For many years, I have focused on aspects of lifestyle and health management that can enhance quality of life, especially when living with a chronic disease like diabetes, rather than simply on living a long time (longevity). Much of my motivation is derived from the personal experience of watching my maternal grandmother suffer through six (long) years of severe disability related to cardiovascular complications of diabetes starting at the age of 70 that left her unable to feed herself or communicate, bed bound, and with almost no quality of life for her final six years of life. Really, what is the point of simply being alive when you’re really not experiencing life under such conditions?